Table 1.

Clinicopathologic characteristics of breast carcinomas with positive NKX3.1 labelling

Case	Age	Race	Type	Elston Grade	Pathologic Stage	Tumour Size (cm)	Phenotype	ER %	PR %	AR %	NKX3.1 (%)	Her2 Status
1	60	W	IDC	II	T1N1	2	Luminal A	95 S	70 S	90 S	5	Negative
2	73	B	IDC	I	T2N1mi	3	Luminal A	100 S	100 S	95 MS	30	Negative
3	42	W	ILC	II	T3N1mi	5.7	Luminal A	90 S	80 MS	90 S	<5	Negative
4	41	W	ILC	II	T2N1mi	2.1	Luminal B	80 MS	90 S	60 M	90	Positive
5	52	W	ILC	II	T2N1	2.6	Luminal A	90 S	70 S	85 S	5–10	Negative
6	47	O	ILC	II	T2N2	2.4	Luminal A	95 S	75 S	95 S	<5	Negative
7	57	U	ILC	I	T1N0	1.6	Luminal A	95 S	5 M	90 S	10	Negative
8	68	W	ILC	II	T2N0	2.5	Luminal A	90 MS	50 MS	75 M	25	Negative
9	68	W	ILC	II	T1N0	1.8	Luminal A	100 S	100 S	95 S	50	Negative
10	41	W	ILC	II	T2N0	3.3	Luminal A	75 MS	65 MS	80 MS	<5	Negative
11	75	W	ILC	I	T3N1mi	8	Luminal A	95 S	80 M	85 MS	<5	Negative
12	79	W	ILC	I	T2N0	2.2	Luminal A	95 S	90 S	90 S	100	Negative

AR, androgen receptor; B; black; cm, centimetres; ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; M, moderate; MS, moderate-strong; N, node; O, other; PR, progesterone receptor; S, strong; T, tumour; U, unknown; W, white.